Neurotensin

Overview

Neurotensin (NT) is a 13-amino-acid peptide first isolated from bovine hypothalamus in 1973 by Robert Carraway and Susan Leeman. It functions as both a neuropeptide in the central nervous system and a paracrine/endocrine hormone in the gastrointestinal tract. In the brain, neurotensin is closely associated with dopaminergic and glutamatergic systems, and its signaling profile has been described as mimicking the effects of antipsychotic drugs. In the periphery, it is released from enteroendocrine N cells of the small intestine in response to dietary fat and regulates intestinal motility, pancreatic and biliary secretion, and fat absorption. Neurotensin acts through GPCR signaling.

The peptide derives its name from its dual neural and endocrine nature. Neurotensin research has attracted interest from multiple fields including psychiatry (endogenous antipsychotic hypothesis), oncology (tumor growth promotion), and metabolic science (fat absorption and obesity).

Structure and Pharmacology

Molecular characteristics:

• Sequence: pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu
• Length: 13 amino acids
• Molecular weight: 1,672.9 Da
• Active fragment: NT(8-13) (Arg-Arg-Pro-Tyr-Ile-Leu) retains full biological activity at all receptor subtypes
• Key features: Pyroglutamate N-terminus; C-terminal hexapeptide contains the receptor-binding pharmacophore

Neurotensin Receptors

Neurotensin signals through three identified receptors:

NTS1 (NTSR1):

• Class A GPCR, Gq-coupled
• Primary mediator of neurotensin's central and peripheral effects
• Activates phospholipase C, IP3/calcium, and MAPK pathways
• Expressed in brain (ventral tegmental area, nucleus accumbens, hypothalamus), intestine, pancreas, and various tumor types

NTS2 (NTSR2):

• Class A GPCR with lower affinity for NT
• Involved in pain modulation (analgesic effects)
• Expressed in brain and spinal cord
• Primarily Gq-coupled; may also engage Gi pathways

NTS3 (SORT1/Sortilin):

• A single-transmembrane type I receptor (Vps10p domain sorting receptor)
• Not a classical GPCR; involved in intracellular sorting, pro-neurotrophin signaling, and lipoprotein metabolism
• Binds neurotensin and pro-neurotensin
• Implicated in cardiovascular disease risk through effects on VLDL metabolism

Central Nervous System Functions

Dopamine modulation: Neurotensin is anatomically and functionally intertwined with the mesolimbic and nigrostriatal dopaminergic pathways:

• NT-containing neurons in the ventral tegmental area (VTA) directly modulate dopaminergic neuron activity
• NTS1 activation on dopamine neurons produces effects that parallel antipsychotic drugs: reduced dopamine release in the nucleus accumbens, catalepsy at high doses, and hypothermia
• Unlike typical antipsychotics, neurotensin may preferentially modulate mesolimbic over nigrostriatal dopamine, suggesting potential for antipsychotic effects without extrapyramidal side effects

Analgesia:

• Central and peripheral neurotensin administration produces opioid-independent analgesia
• NTS2 activation is particularly associated with analgesic effects
• Neurotensin analgesic mechanisms involve descending pain inhibitory pathways

Thermoregulation:

• Central neurotensin administration produces hypothermia via modulation of hypothalamic thermosensitive neurons

Feeding behavior:

• Central neurotensin acts as an anorectic peptide, reducing food intake
• NT signaling in the hypothalamus interacts with leptin, Neuropeptide Y, and melanocortin pathways

Peripheral Functions

Gastrointestinal:

• Released from N cells in response to dietary fat (particularly long-chain fatty acids)
• Stimulates pancreatic and biliary secretion
• Inhibits gastric acid secretion and gastric motility
• Facilitates intestinal fat absorption and mucosal growth

Cardiovascular:

• Causes hypotension via vasodilation (histamine-dependent and -independent mechanisms)
• Increases vascular permeability
• Modulates cardiac function

Clinical and Research Significance

Psychiatry

The "neurotensin hypothesis of schizophrenia" posits that deficient neurotensin signaling may contribute to schizophrenia pathophysiology. Supporting evidence includes reduced CSF neurotensin levels in some schizophrenia patients, normalization of NT levels with effective antipsychotic treatment, and the antipsychotic-like behavioral profile of NT agonists in animal models. NTS1 agonists and NT analogs with improved Blood-brain barrier penetrance have been investigated as potential novel antipsychotics.

Oncology

Neurotensin and NTS1 are implicated in the progression of several cancers:

• Colorectal cancer: NTS1 is upregulated in a significant proportion of colorectal adenocarcinomas; NT/NTS1 signaling promotes proliferation, migration, and invasion
• Pancreatic cancer: NT stimulates pancreatic cancer cell growth via NTS1-mediated MAPK and PI3K-Akt activation
• Breast cancer: NTS1 expression correlates with aggressive phenotype and poor prognosis
• Small cell lung cancer: NT may function as an autocrine growth factor

NTS1 antagonists and NT-targeted imaging agents are under investigation for both therapeutic and diagnostic applications in oncology.

Metabolic Research

Circulating neurotensin levels have been associated with metabolic parameters in epidemiological studies. Elevated pro-NT levels (the stable NT precursor fragment used as a surrogate biomarker, since mature NT is rapidly degraded) have been linked to increased risk of diabetes, cardiovascular disease, and breast cancer in prospective cohort studies. The NTS3/sortilin pathway intersects with lipoprotein metabolism, and sortilin polymorphisms are associated with LDL cholesterol levels.

Pharmacokinetics

Mature neurotensin has an extremely short plasma Half-life of approximately 30 seconds to 2 minutes, owing to rapid degradation by metalloendopeptidases (neprilysin/NEP 24.11, endopeptidase 24.15, and angiotensin-converting enzyme). This rapid clearance limits the therapeutic utility of native NT and has driven the development of stabilized analogs, cyclic peptides, and peptidomimetics for research and potential clinical application.

Dosing Protocols

As an endogenous neuropeptide, neurotensin is not typically administered exogenously in clinical practice. It is primarily studied as a biomarker or through receptor-targeted interventions. Neurotensin receptor agonists and antagonists are in preclinical development for pain, schizophrenia, and oncology applications. Pro-neurotensin (stable precursor fragment) is measured clinically as a biomarker associated with metabolic syndrome, cardiovascular risk, and breast cancer prognosis. The rapid degradation of native neurotensin in vivo limits direct therapeutic utility.

Research Directions

Current neurotensin research focuses on developing metabolically stable NTS1 agonists as novel antipsychotics, NTS2-selective agonists for non-opioid pain management, NTS1 antagonists for cancer therapy, and NT-conjugated nanoparticles for tumor-targeted drug delivery. The peptide's involvement in dopaminergic regulation, pain processing, cancer biology, and metabolic homeostasis makes it one of the most functionally diverse neuropeptides under active investigation.